loike

Data don’t support many direct-to-consumer products, from telomere assessments to bespoke diets based on genetic sequences.

The use of pronuclear transfer to treat infertility must first be backed by evidence it can work in cases where parents seek to avoid mitochondrial mutations.

Determining which products of advanced biotechnology are deserving of legal protections is essential to our own social architecture.

Meet some of the people featured in the January 2017 issue of The Scientist.

Expensive clinical trials and few drug approvals can drive up drug prices for consumers.

March for science debate; an RNA vaccine for Zika; responses to Trump’s immigration order; native habitat restoration; views from local March for Science organizers; artificial cells and the Turing test

What can be done to lower development costs and drug prices?

Mitochondrial replacement therapy raises important societal and ethical concerns, but should be embraced for its utility in preventing disease.

This year, the developers of CRISPR gene-editing technology argued over patent rights, a researcher fought to unmask anonymous PubPeer commenters, US regulators considered “three-parent” babies, and troubles continued for Theranos.

We should not resist developing opiate-producing GM yeast for fear of the technology falling into the wrong hands.